EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease

Owen Cronin, Olivia McKnight, Lindsay Keir, Stuart H Ralston, Nikhil Hirani, Helen Harris

Rheumatology International · 2021-05 · 41 (5) · 921-928

DOI: 10.1007/s00296-021-04835-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Rheumatology International, online erschienen am 15.03.2021. Verfasst von Owen Cronin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatic Diseases Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. ocronin@ed.ac.uk. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors (JAKi) are an exciting option for the treatment of rheumatoid arthritis (RA) but little is known about their safety and tolerability in patients with existing respiratory disorders. The objective was to compare pulmonary safety of JAKi versus rituximab in patients with concurrent interstitial lung disease (ILD) or bronchiectasis. We performed a retrospective electronic patient record review of patients with known ILD or bronchiectasis commencing JAKi or rituximab for the treatment of RA. Patients initiating treatment from January 2016 to February 2020 were included. Respiratory events (hospitalization or death from a respiratory cause) were compared using Kaplan–Meier survival analysis. We analysed patients who received JAKi ( n = 28) and rituximab ( n = 19) for a mean (SD) of 1.1 (0.62) and 2.14 (1) years respectively. Patients were predominantly female (68%), anti-CCP antibody positive (94%) and non-smoking (89%) with a median (IQR) percentage predicted FVC at baseline of 100% (82–115%) and percentage predicted TL CO of 62% (54.5–68%). Respiratory events occurred in five patients treated with JAKi (18%; 5 hospitalizations, 2 deaths) and in four patients treated with rituximab (21%; 3 hospitalizations, 1 death). Respiratory event rates did not differ between groups (Cox-regression proportional hazard ratio = 1.38, 95% CI 0.36–5.28; p = 0.64 ). In this retrospective study, JAKi for the treatment of RA with existing ILD or bronchiectasis did not increase the rate of hospitalization or death due to respiratory causes compared to those treated with rituximab. JAK inhibition may provide a relatively safe option for RA in such patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAntirheumatic AgentsArthritis, RheumatoidBronchiectasisFemaleHospitalizationHumansJanus Kinase InhibitorsKaplan-Meier EstimateLung Diseases, InterstitialMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesRituximab

Stichwörter der Autor:innen

BronchiectasisInterstitial lung diseaseJanus kinasesRheumatoid arthritisRituximab

Substanzen

Antirheumatic AgentsJanus Kinase InhibitorsRituximab

Autor:innen und Institutionen

  • Rheumatic Diseases Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. ocronin@ed.ac.uk.
  • College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK. ocronin@ed.ac.uk.
  • Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK. ocronin@ed.ac.uk.
  • Rheumatic Diseases Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK.
  • Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.

Förderung

  • Medical Research Council

Zitieren

APA

Cronin, O., McKnight, O., Keir, L., Ralston, S. H., Hirani, N., & Harris, H. (2021). A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatology International, 41(5), 921-928. https://doi.org/10.1007/s00296-021-04835-1

Vancouver

Cronin O, McKnight O, Keir L, Ralston SH, Hirani N, Harris H. A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatology International. 2021;41(5):921-928. doi:10.1007/s00296-021-04835-1

BibTeX
@article{Cronin2021,
  author = {Cronin, Owen and McKnight, Olivia and Keir, Lindsay and Ralston, Stuart H and Hirani, Nikhil and Harris, Helen},
  title = {A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease},
  journal = {Rheumatology International},
  year = {2021},
  volume = {41},
  number = {5},
  pages = {921--928},
  doi = {10.1007/s00296-021-04835-1}
}
Kostenlos starten →